BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA

BioMarin Pharmaceutical Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA). The company intends to submit an application for registration in the European Union (EU) by the end of April 2013. Read the full press release.

This entry was posted in News and tagged . Bookmark the permalink.

Comments are closed.